Catalog No.
VHC98801
Species reactivity
Human
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Applications
ELISA, Neutralization
Target
ITGA4, CD49d, CD49 antigen-like family member D, CD49D, VLA-4 subunit alpha, Integrin alpha-IV, Integrin alpha-4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P13612
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0201
Note
For research use only. Not suitable for clinical or therapeutic use.
Recruitment of α4β7 monocytes and neutrophils to the brain in experimental colitis is associated with elevated cytokines and anxiety-like behavior., PMID:35379260
Co-Expression of the B-Cell Key Transcription Factors Blimp-1 and IRF4 Identifies Plasma Cells in the Pig., PMID:35464468
Adhesion Molecule Profile and the Effect of Anti-VLA-4 mAb Treatment in Experimental Autoimmune Encephalomyelitis, a Mouse Model of Multiple Sclerosis., PMID:35563027
Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling., PMID:35628269
Blocking immune cell infiltration of the central nervous system to tame Neuroinflammation in Amyotrophic lateral sclerosis., PMID:35688338
Biomechanical changes in the liver tissue induced by a mouse model of multiple sclerosis (EAE) and the effect of anti-VLA-4 mAb treatment., PMID:35868535
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response., PMID:35913400
The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives., PMID:36062026
In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis., PMID:36171212
Göttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation., PMID:36308917
Improving IBD outcomes in the era of many treatment options., PMID:36635556
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis., PMID:36810163
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials., PMID:36876333
Alpha4 beta7 integrin controls Th17 cell trafficking in the spinal cord leptomeninges during experimental autoimmune encephalomyelitis., PMID:37143680
High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4+ T cell arrest on the inflamed BBB under flow in vitro., PMID:37221552
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease., PMID:37235690
Differential Effects of Anti-PD-1/PD-L1 Checkpoint Inhibitors on Adhesion Molecules and Cytokine Secretion by THP-1 Monocytes., PMID:37247886
Notch signaling drives intestinal graft-versus-host disease in mice and nonhuman primates., PMID:37379368
Distinct CRTH2+CD161+ (peTh2) memory CD4+ T-cell cytokine profiles in food allergy and eosinophilic gastrointestinal disorders., PMID:37487654
Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis., PMID:37548395
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment., PMID:37739811
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis., PMID:37752582
Effects of a gut-selective integrin-targeted therapy in male mice exposed to early immune activation, a model for the study of autism spectrum disorder., PMID:37793488
ANTI-CD49D ANTIBODY TREATMENT IMPROVES SURVIVAL AND ATTENUATES NEUROCOGNITIVE DEFICITS AFTER TRAUMATIC BRAIN INJURY IN AGED MICE., PMID:38010092
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial., PMID:38044885
Sequential engagement of adhesion molecules and cytokine receptors impacts both piecemeal and anaphylactic degranulation of human basophils., PMID:38226657
HDAC1/2 control mesothelium/ovarian cancer adhesive interactions impacting on Talin-1-α5β1-integrin-mediated actin cytoskeleton and extracellular matrix protein remodeling., PMID:38254102
Imaging Very Late Antigen-4 on MOLT4 Leukemia Tumors with Cysteine Site-Specific 89Zr-Labeled Natalizumab Immuno-Positron Emission Tomography., PMID:38282332
Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells., PMID:38310086
BV2 Membrane-Coated PEGylated-Liposomes Delivered hFGF21 to Cortical and Hippocampal Microglia for Alzheimer's Disease Therapy., PMID:38513154
Flow cytometric immunophenotypic differentiation patterns of bone marrow eosinophilopoiesis., PMID:38666394
PB006: A Natalizumab Biosimilar., PMID:38683493
Long-lasting severe anemia following treatment with natalizumab for relapsing-remitting multiple sclerosis: a case report., PMID:38736000
A novel surface marker CD49d promotes TNF expression in oyster agranulocytes by mediating the MAPK pathway., PMID:38897309
miR-200c-3p regulates α4 integrin-mediated T cell adhesion and migration., PMID:38936759
antiCD49d Ab treatment ameliorates age-associated inflammatory response and mitigates CD8+ T-cell cytotoxicity after traumatic brain injury., PMID:38948775
Longitudinal Intravascular Antibody Labeling Identified Regulatory T Cell Recruitment as a Therapeutic Target in a Mouse Model of Lung Cancer., PMID:39082930
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands., PMID:39143370
[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins]., PMID:39176460
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis., PMID:39393045
Anti-CD49d Ab treatment ameliorates age-associated inflammatory response and mitigates CD8+ T-cell cytotoxicity after traumatic brain injury., PMID:39427160
Investigating the effect of immunomagnetic separation on the immunophenotype and viability of plasma cells in plasma cell disorders., PMID:39493694
Neutrophils in the Spotlight-An Analysis of Neutrophil Function and Phenotype in ARDS., PMID:39684262
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia., PMID:39716442
Anti-PD1-/PDL1-induced chronic intestinal pseudo-obstruction: three cases treated with vedolizumab after corticosteroid failure with mixed results., PMID:39751892
Triple knockdown of CD11a, CD49d, and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice., PMID:39841806
Integrin beta 1 and fibronectin mediate extracellular vesicle uptake and functional RNA delivery., PMID:39947471
B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis., PMID:40010950
A proteogenomic tool uncovers protein markers for human microglial states., PMID:40236015
Rare Subset of T Cells Form Heterotypic Clusters with Circulating Tumor Cells to Foster Cancer Metastasis., PMID:40236049
For research use only. Not for human or drug use.
